Hochschulschrift
Gene expression profiling based identifications of potential prognostic molecular markers in decitabine treated acute myeloid leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Ulm, Universität Ulm, Dissertation, 2016
- Keyword
-
Akute myeloische Leukämie
Genexpression
Krebs
Onkologie
- DOI
-
10.18725/OPARU-3972
- URN
-
urn:nbn:de:bsz:289-oparu-4011-3
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Bohl, Stephan
- Universität Ulm
Time of origin
- 2016
Other Objects (12)
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
Region-Specific Methylation Profiling in Acute Myeloid Leukemia
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
Region-Specific Methylation Profiling in Acute Myeloid Leukemia
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
The clinical value of decitabine monotherapy in patients with acute myeloid leukemia
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
Region-Specific Methylation Profiling in Acute Myeloid Leukemia
The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis